Plasma cell leukemia.

S. R. Hayman, Rafael Fonseca

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM. Secondary PCL represents a terminal event for refractory/relapsed MM and is usually not responsive to any treatment modality. The optimal regimens for the treatment of primary PCL have not been firmly established. Induction with combination chemotherapy, followed by high-dose chemotherapy (preferably within the setting of a clinical trial), is the current recommended approach for eligible patients.

Original languageEnglish (US)
Pages (from-to)205-216
Number of pages12
JournalCurrent Treatment Options in Oncology
Volume2
Issue number3
StatePublished - Jun 2001

Fingerprint

Plasma Cell Leukemia
Multiple Myeloma
Combination Drug Therapy
Therapeutics
Clinical Trials
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Plasma cell leukemia. / Hayman, S. R.; Fonseca, Rafael.

In: Current Treatment Options in Oncology, Vol. 2, No. 3, 06.2001, p. 205-216.

Research output: Contribution to journalArticle

Hayman, SR & Fonseca, R 2001, 'Plasma cell leukemia.', Current Treatment Options in Oncology, vol. 2, no. 3, pp. 205-216.
Hayman, S. R. ; Fonseca, Rafael. / Plasma cell leukemia. In: Current Treatment Options in Oncology. 2001 ; Vol. 2, No. 3. pp. 205-216.
@article{faf9b1aa61064e3baa2fc39197212b9e,
title = "Plasma cell leukemia.",
abstract = "Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM. Secondary PCL represents a terminal event for refractory/relapsed MM and is usually not responsive to any treatment modality. The optimal regimens for the treatment of primary PCL have not been firmly established. Induction with combination chemotherapy, followed by high-dose chemotherapy (preferably within the setting of a clinical trial), is the current recommended approach for eligible patients.",
author = "Hayman, {S. R.} and Rafael Fonseca",
year = "2001",
month = "6",
language = "English (US)",
volume = "2",
pages = "205--216",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Plasma cell leukemia.

AU - Hayman, S. R.

AU - Fonseca, Rafael

PY - 2001/6

Y1 - 2001/6

N2 - Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM. Secondary PCL represents a terminal event for refractory/relapsed MM and is usually not responsive to any treatment modality. The optimal regimens for the treatment of primary PCL have not been firmly established. Induction with combination chemotherapy, followed by high-dose chemotherapy (preferably within the setting of a clinical trial), is the current recommended approach for eligible patients.

AB - Plasma cell leukemia (PCL) is a rare aggressive variant of multiple myeloma (MM) characterized by a fulminant course and poor prognosis. The median survival is measured in months. Therapy and prognosis partially depend on whether the disease presents de novo or as a secondary process involving the leukemic transformation of a previously diagnosed MM. Secondary PCL represents a terminal event for refractory/relapsed MM and is usually not responsive to any treatment modality. The optimal regimens for the treatment of primary PCL have not been firmly established. Induction with combination chemotherapy, followed by high-dose chemotherapy (preferably within the setting of a clinical trial), is the current recommended approach for eligible patients.

UR - http://www.scopus.com/inward/record.url?scp=0035383352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035383352&partnerID=8YFLogxK

M3 - Article

C2 - 12057120

AN - SCOPUS:0035383352

VL - 2

SP - 205

EP - 216

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 3

ER -